000			02082 a2200565 4500
005			20250517233130.0
264		0	_c20190403
008			201904s 0 0 eng d
022			_a1873-5835
024	7		_a10.1016/j.leukres.2018.08.005 _2doi
040			_aNLM _beng _cNLM
100	1		_aZeidner, Joshua F
245	0	0	_aFinal results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML). _h[electronic resource]
260			_bLeukemia research _c09 2018
300			_a92-95 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Comparative Study; Letter; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage
650	0	4	_aCytarabine _xadministration & dosage
650	0	4	_aDaunorubicin _xadministration & dosage
650	0	4	_aFemale
650	0	4	_aFlavonoids _xadministration & dosage
650	0	4	_aHumans
650	0	4	_aLeukemia, Myeloid, Acute _xdiagnosis
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMitoxantrone _xadministration & dosage
650	0	4	_aPiperidines _xadministration & dosage
650	0	4	_aRisk Factors
700	1		_aFoster, Matthew C
700	1		_aBlackford, Amanda L
700	1		_aLitzow, Mark R
700	1		_aMorris, Lawrence E
700	1		_aStrickland, Stephen A
700	1		_aLancet, Jeffrey E
700	1		_aBose, Prithviraj
700	1		_aLevy, M Yair
700	1		_aTibes, Raoul
700	1		_aGojo, Ivana
700	1		_aGocke, Christopher D
700	1		_aRosner, Gary L
700	1		_aLittle, Richard F
700	1		_aWright, John J
700	1		_aDoyle, L Austin
700	1		_aSmith, B Douglas
700	1		_aKarp, Judith E
773	0		_tLeukemia research _gvol. 72 _gp. 92-95
856	4	0	_uhttps://doi.org/10.1016/j.leukres.2018.08.005 _zAvailable from publisher's website
999			_c28740924 _d28740924